Our unique approach to cell reprogramming combines high-throughput sequencing data with gene-regulatory networks using our proprietary mogrify technology in order to reprogram between any two human cell types. Our integration of cutting-edge machine learning with world-class experimental protocols is the key to generating complete conversions and maximising their efficiency and has enabled us to develop over 20 novel conversions in the last year, with more underway. Our mission is to use data-driven methods to remove the aspect of trial and error from the development of regenerative medicines.

As well as our own regenerative medicine products we also partner with life science companies to develop cell reprogramming protocols for new therapies in regenerative medicine and advanced cancer treatments.